Results for tag: "Opdivo"

Opdivo (nivolumab) is a monoclonal antibody drug used to treat non-small cell lung cancer (NSCLC). It works by blocking the activity of a protein called PD-1, which helps cancer cells evade the body's immune system. Opdivo is approved for use in combination with other drugs to treat advanced NSCLC, and is also used to treat other types of cancer, including melanoma and renal cell carcinoma. Opdivo is part of a class of drugs known as immune checkpoint inhibitors, which are designed to help the body's immune system recognize and attack cancer cells. It is one of the most widely used drugs for treating NSCLC, and is often used in combination with other drugs to improve outcomes. Opdivo is marketed by Bristol-Myers Squibb, and is available in the United States, Europe, and other countries. Other companies that market similar drugs include Merck, AstraZeneca, and Roche. Show Less Read more